Organigram Global Inc. - Common Shares (OGI)

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the “Company” or “Organigram”), Canada's #1 cannabis company by market share¹ and a growing global cannabis platform, today announced that on November 11, 2026, it received notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market. The Notification was issued because the closing bid price of the Company's common shares was below US$1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5450(a)(1) requires listed common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), while Nasdaq Listing Rule 5810(c)(3)(A) provides that a deficiency exists when the requirement is not met for 30 consecutive business days.

Organigram is valuing Aurora Cannabis more highly than Curleaf, but that doesn't mean it's the best option for shareholders in the long run.

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”).

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1 and a growing global cannabis platform, today provided an update on the previously announced accelerated integration of Sanity Group GmbH (“Sanity Group”) and unified global operating model, which completes the integration of Sanity Group and aligns the Company as one enterprise. The Company expects these actions, which include a series of operating efficiencies concentrated in its Canadian business, to deliver annualized run-rate cost savings in the range of $8 million to $10 million in Fiscal 2027, advancing the profitability of the business and supporting disciplined global growth.

Organigram Global (NASDAQ:OGI) outlined a strategy centered on protecting its Canadian market position while increasing profitability, expanding internationally through its Sanity Group acquisition, improving manufacturing efficiency and applying stricter capital-allocation discipline. At its 2026

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram") is pleased to announce that the 2026 OG Investor Session will premiere today, September 30, 2026, at 4:00 p.m. ET on the Company's X account at https://x.com/Organigram_Inc.

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today announced details of its 2026 OG Investor Session.

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its global growth strategy through the accelerated integration of Sanity Group GmbH (“Sanity”) and the alignment of leadership, operations and market development activities across the combined organization.

Revenue jumped 49% to $105.8 million on Sanity acquisition.

Organigram Global (NASDAQ:OGI) reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories. Net revenue rose 49% year over year to C$105.8 million, while adjusted EB

Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global (NASDAQ:OGI)

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”).

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), announced today it will report earnings results for its third quarter ended June 30, 2026, on Tuesday, August 11, 2026, prior to market open.

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), today provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement.

EQNX::TICKER_START (OTCQB:LUFFF),(CSE:HERB),(NASDAQ:ACB),(NASDAQ:TLRY),(NASDAQ:CGC),(NASDAQ:OGI) EQNX::TICKER_END

Germany and other key markets are fueling rising demand for regulated cannabis products and infrastructure

Organigram Global (NASDAQ:OGI) reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market growth and continued challenges with international flower specifications. Chief Executive Officer

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2").

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open.

EQNX::TICKER_START (OTCQB:LUFFF),(CSE:HERB),(NASDAQ:TLRY),(NASDAQ:CGC),(NASDAQ:SNDL),(NASDAQ:OGI),(TSX:WEED),(CSE:SNDL) EQNX::TICKER_END

Innovative product formats and growing global acceptance are fueling a powerful long-term growth trajectory

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) and Sanity Group GmbH (“Sanity” or “Sanity Group”) jointly announced the successful closing of Organigram’s previously announced acquisition (the “Acquisition”) of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026 (the “Share Purchase Agreement”). In connection with closing of the Acquisition, a wholly owned subsidiary of the Company acquired all of the issued and outstanding shares of Sanity Group not already owned by the Company for an upfront purchase price paid on closing of €107.3 million, consisting of €78.0 million in cash and €29.3 million in share consideration (the “Upfront Consideration”). In connection with the closing of the Acquisition, the Company also closed its previously announced private placement financing (the “Private Placement”) with BT DE Investments Inc. (“BAT”), a wholly owned subsidiary of British American Tobacco p.l.c.1, for total gross proceeds of €40.3 million (equal to C$65.2 million)2, and its previously announced senior secured credit facilities (the “Loan Facilities”) of up to C$60 million.

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to consummate the previously announced acquisition by the Company (the “Transaction”) of Sanity Group GmbH (“Sanity Group”) and the related private placement financing (the “Private Placement”) with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco (“BAT”) at the Company’s annual general and special meeting of shareholders (the “Shareholders”) held on March 30, 2026 (the “Meeting”).